|
US2951014A
(en)
|
1957-01-03 |
1960-08-30 |
Upjohn Co |
Process for a stable oil suspension
|
|
SE9900961D0
(sv)
|
1999-03-16 |
1999-03-16 |
Astra Ab |
Novel compounds
|
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
|
WO2004004682A2
(en)
|
2002-07-02 |
2004-01-15 |
Laboratorios S.A.L.V.A.T., S.A. |
Stable oily suspension of microgranules
|
|
EP1599216B9
(en)
|
2003-02-04 |
2015-02-11 |
Cornell Research Foundation, Inc. |
Methods for preventing mitochondrial permeability transition
|
|
PL2604286T3
(pl)
|
2003-05-01 |
2015-03-31 |
Cornell Res Foundation Inc |
Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
|
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
|
CA3024434A1
(en)
|
2004-01-23 |
2005-08-11 |
Cornell Research Foundation, Inc. |
Methods for reducing oxidative damage
|
|
US20050181050A1
(en)
|
2004-01-28 |
2005-08-18 |
Collegium Pharmaceutical, Inc. |
Dosage forms using drug-loaded ion exchange resins
|
|
US7745459B2
(en)
|
2004-09-21 |
2010-06-29 |
Japan Tobacco Inc. |
Quinolizinone compound and use thereof as HIV integrase inhibitor
|
|
CN104788540B
(zh)
|
2005-09-16 |
2019-10-18 |
科内尔研究基金会 |
用于减少cd36表达的方法
|
|
AU2012202035B2
(en)
|
2005-09-16 |
2014-03-20 |
Cornell Research Foundation, Inc. |
Methods for reducing CD36 expression
|
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
|
WO2007122624A2
(en)
|
2006-04-24 |
2007-11-01 |
Technion Research And Development Foundation Ltd. |
Non-covalent complexes of bioactive agents with starch for oral delivery
|
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
BRPI0717721A2
(pt)
*
|
2006-11-28 |
2013-10-29 |
Marinus Pharmaceuticals |
"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
|
|
EP2712620A1
(en)
|
2008-02-07 |
2014-04-02 |
Cornell University |
Methods for Preventing or Treating Insulin Resistance
|
|
EP3741381B1
(en)
|
2008-02-26 |
2024-04-24 |
Cornell University |
A peptide for use for prevention and treatment of acute renal injury
|
|
US20110105417A1
(en)
|
2008-06-26 |
2011-05-05 |
The Curators Of The University Of Missouri |
Drug Conjugates
|
|
US8323615B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing multi-phasic dispersions
|
|
WO2011019809A1
(en)
|
2009-08-12 |
2011-02-17 |
Cornell University |
Methods for preventing or treating metabolic syndrome
|
|
WO2011044044A1
(en)
|
2009-10-05 |
2011-04-14 |
Cornell University |
Methods for the prevention or treatment of heart failure
|
|
CA2787331A1
(en)
|
2010-01-25 |
2011-07-28 |
Hazel H. Szeto |
Aromatic-cationic peptides and uses of same
|
|
JP2013521231A
(ja)
|
2010-02-26 |
2013-06-10 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド |
ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
|
|
CN106913860A
(zh)
|
2011-09-29 |
2017-07-04 |
梅约医学教育与研究基金会 |
芳族阳离子肽和使用它们的方法
|
|
CN104203262A
(zh)
|
2012-02-23 |
2014-12-10 |
康奈尔大学 |
芳香族阳离子肽及其用途
|
|
US10111956B2
(en)
*
|
2013-06-03 |
2018-10-30 |
Tolmar, Inc. |
Corticosteroid compositions
|
|
CA2925475A1
(en)
|
2013-09-27 |
2015-04-02 |
Cornell University |
Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
|
|
EP3052115A4
(en)
|
2013-09-30 |
2017-09-27 |
Cornell University |
Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
|
|
US9895410B2
(en)
|
2013-12-12 |
2018-02-20 |
Cornell University |
Methods for preventing and treating oral cancers
|
|
US20170007663A1
(en)
|
2013-12-16 |
2017-01-12 |
Cornell University |
Methods and compositions for treating and preventing cognitive dysfunction
|
|
WO2016001042A1
(en)
|
2014-06-30 |
2016-01-07 |
Flamma S.P.A. |
Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
|
|
RU2017105844A
(ru)
|
2014-08-08 |
2018-09-11 |
Форсайт Вижн4, Инк. |
Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
|
|
WO2016057809A1
(en)
|
2014-10-10 |
2016-04-14 |
Therakine |
Mg stearate - based composite nanoparticles, methods of preparation and applications
|
|
HUP1500055A1
(hu)
*
|
2015-02-09 |
2016-08-29 |
Druggability Technologies Ip Holdco Ltd |
Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
|
|
US20170224764A1
(en)
|
2016-02-10 |
2017-08-10 |
Cornell University |
Therapeutic targeting of mitochondria to prevent osteoarthritis
|
|
WO2017180535A1
(en)
|
2016-04-11 |
2017-10-19 |
Carnot, Llc |
Chiral peptides
|
|
JP2019515925A
(ja)
|
2016-04-29 |
2019-06-13 |
エンセラドゥス ファーマセウティカルス べー．フェー． |
炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド
|
|
EP3257863A1
(en)
|
2016-06-16 |
2017-12-20 |
Université de Strasbourg |
Flourous metabolically stable peptide analogs
|
|
EP3500286A4
(en)
|
2016-08-16 |
2020-03-25 |
Stealth BioTherapeutics Corp |
N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID
|
|
PL3548091T3
(pl)
*
|
2016-11-29 |
2022-03-28 |
Oculis SA |
Otrzymywanie stałych kompleksów cyklodekstryny do dostarczenia czynnego składnika farmaceutycznego do oczu
|
|
WO2019113432A1
(en)
|
2017-12-08 |
2019-06-13 |
University Of Washington |
Methods and compositions for detecting and promoting cardiolipin remodeling and cardiomyocyte maturation and related methods of treating mitochondrial dysfunction
|
|
US10676506B2
(en)
|
2018-01-26 |
2020-06-09 |
Stealth Biotherapeutics Corp. |
Crystalline bis- and tris-hydrochloride salt of elamipretide
|
|
KR20250010134A
(ko)
|
2018-04-02 |
2025-01-20 |
스텔스 바이오테라퓨틱스 인코포레이티드 |
엘라미프레티드의 합성에 유용한 결정질 디펩티드
|
|
WO2019246141A1
(en)
|
2018-06-19 |
2019-12-26 |
Cella Therapeutics, Llc |
DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE
|
|
KR20210053877A
(ko)
|
2018-06-26 |
2021-05-12 |
리보노바 인크. |
미토콘드리아 기능장애를 치료하는 방법
|
|
EP3986424A1
(en)
|
2019-06-20 |
2022-04-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Composites and uses thereof
|